:: Library Catalog

Copertina

Salvato in:

Dettagli Bibliografici
Autori principali:	Palak J. Trivedi, Katherine Arndtz, Nadir Abbas, Alison Telford, Liam Young, Rajarshi Banerjee, Peter Eddowes, Kartik S. Jhaveri, Gideon M. Hirschfield
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	https://onlinelibrary.wiley.com/doi/10.1111/apt.17944
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis?
di: John E. Eaton, et al.
Pubblicazione: (2024)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
di: D. Bogatic, et al.
Pubblicazione: (2024)

Editorial: Patient Reported Outcomes Provide Insight Into Disease Severity for People Living With Primary Sclerosing Cholangitis
di: Aisha Alawi, et al.
Pubblicazione: (2025)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
di: Ayesha Shah, et al.
Pubblicazione: (2024)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
di: Jörn M. Schattenberg, et al.
Pubblicazione: (2026)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
di: J. M. Schattenberg, et al.
Pubblicazione: (2026)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
di: Amanda Ricciuto, et al.
Pubblicazione: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
di: María Hernández‐Pérez, et al.
Pubblicazione: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
di: Lukas Burghart, et al.
Pubblicazione: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?
di: Guilherme Grossi Lopes Cançado
Pubblicazione: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
di: C. M. Fernández‐Rodríguez, et al.
Pubblicazione: (2024)

Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study
di: Kris V. Kowdley, et al.
Pubblicazione: (2025)

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis
di: Nadir Abbas, et al.
Pubblicazione: (2025)

Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial
di: Cynthia Levy, et al.
Pubblicazione: (2026)

Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis?
di: Richard Kozarek
Pubblicazione: (2024)

Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis? Authors' reply
di: Yu Liu, et al.
Pubblicazione: (2024)

Long‐term clinical outcomes of extracorporeal shockwave lithotripsy and endoscopic retrograde cholangiopancreatography for pancreatic duct stone treatment in patients with chronic pancreatitis
di: Yu Liu, et al.
Pubblicazione: (2024)

Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study
di: Elena Vargas‐Accarino, et al.
Pubblicazione: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
di: Lana Bridi, et al.
Pubblicazione: (2024)

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
di: Nikita Mittal, et al.
Pubblicazione: (2024)

Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study
di: Harris Siddiqi, et al.
Pubblicazione: (2024)

Prevalence and prognosis of patients with MASLD ‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study
di: Philippe Sultanik, et al.
Pubblicazione: (2024)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
di: Pardhu Bharath Neelam, et al.
Pubblicazione: (2025)

The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study
di: Fangyuan Jiang, et al.
Pubblicazione: (2024)

Dietary factors and patterns in relation to risk of later‐onset ulcerative colitis in Chinese: A prospective study of 0.5 million people
di: Shuyao Song, et al.
Pubblicazione: (2024)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
di: Stefan Mauss
Pubblicazione: (2025)

Duke Activity Status Index and Liver Frailty Index predict mortality in ambulatory patients with advanced chronic liver disease: A prospective, observational study
di: Felicity R. Williams, et al.
Pubblicazione: (2024)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)

The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity—A prospective biopsy‐controlled study
di: David J. M. Bauer, et al.
Pubblicazione: (2024)

Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study (GUTS)
di: Keming Yang, et al.
Pubblicazione: (2024)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
di: Yee Hui Yeo, et al.
Pubblicazione: (2026)

Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study
di: Maria Mironova, et al.
Pubblicazione: (2024)

No value of non‐selective beta‐blockers after TIPS‐insertion
di: Anja Tiede, et al.
Pubblicazione: (2024)

Editorial: The future of managing drug induced liver injury
di: Amanda Nicoll
Pubblicazione: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
di: Vibeke Strande, et al.
Pubblicazione: (2024)

CD300A+CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy
di: Peng Zhang, et al.
Pubblicazione: (2025)

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies
di: Jasmohan S. Bajaj, et al.
Pubblicazione: (2025)

Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients
di: Ming Liu, et al.
Pubblicazione: (2025)

Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population‐Based Cohort Study
di: Samantha Baillie, et al.
Pubblicazione: (2025)

Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006–2021
di: Mehdi Osooli, et al.
Pubblicazione: (2025)